Rising pump usage and increased market entry of ultra-fast acting insulin formulations may improve the landscape
Dublin, April 21, 2021 (GLOBE NEWSWIRE) – The “Type 1 Diabetes – Global Drug Forecast and Market Analysis to 2029” the report was added to ResearchAndMarkets.com from offer.
The $ 8 million T1D therapeutic market will grow from $ 4.9 billion in 2019 at a significant compound annual growth rate (CAGR) of 17.2% to $ 24 billion by 2029.
In particular, the publisher expects the US market to contribute the most to the growth of the T1D market, contributing $ 4.3 billion in sales in 2019 (87.7% of the T1D market) and to $ 20.3 billion in 2029 (84.7% of the T1D market).
The launch of the first disease-modifying therapy will be the main driver of growth during the forecast period, with the first preventive treatment for T1D, Teplizumab, to be launched in the United States during the forecast period. Other major drivers of the T1D market include the increase in the diagnosed prevalence of T1D and the adoption of new ultra-fast and ultra-long-acting insulin analogs.
Based on the publisher’s epidemiological analysis, diagnosed prevalent cases of T1D in 8MM will increase by 17.79% over the next decade, from 3,329,294 prevalent cases in 2019 to 3,921,695 prevalent cases in 2029, at an annual growth rate (TAG) of 1.78% per year in the eight main pharmaceutical markets (8 MM) covered by this report, the United States, 5 EU (France, Germany, Italy, Spain and United Kingdom) , Japan and Canada.
The consensus among physicians surveyed regarding the current treatment landscape was that while there are a number of insulin treatment options, there are a significant number of patients who are not being managed effectively and therefore , have considerably high unmet needs in the indication.
The Key Opinion Leaders (KOL) interviewed by the publisher highlighted the absence of an anti-disease-modifying treatment that combats the autoimmune beta cell attack in T1D patients. Other major issues include blood sugar control, combating obesity, and overall disease management. Despite a number of drugs currently in development, the publisher’s research suggests that the future level of fulfillment of these unmet needs will be modest, and drug developers will have a relatively high opportunity to enter the drug market. T1D.
- The diagnosed prevalence of T1D is expected to increase over the 10-year forecast period due to changing demographics of the population and a better understanding of the risk factors and environmental factors that can trigger the onset of T1D.
- The potential launch of 5 disease-modifying therapeutic agents will increase the number of patients who, at diagnosis, can prolong their endogenous insulin secretion to improve disease management. These drugs are expected to have a high annual treatment cost (ACOT), a factor that will contribute to notable cost-effectiveness.
- The growing trend of integrating devices into the treatment and management of T1D will have an impact on successful therapeutic products in the market. The trend towards closed-loop systems, such as an artificial pancreas, places a great need for ultra-fast insulins to market and prompts greater collaboration between the entire industry.
- Despite the variety of insulins currently available for T1D patients, there is still room for improvement in the treatment space. Most recognizable is the need for new treatment options for refractory patients.
Main topics covered:
1 Type 1 diabetes: executive summary
1.1 Type 1 diabetes market will grow to $ 24 billion by 2029
1.2 Veteran T1D players use various strategies to defend insulin franchises against biosimilar erosion, while newer players invest in disease modifying space
1.3 Current and future therapies leave significant unmet needs in the market
1.4 Increasing Pump Use and Increased Market Entry of Ultra-Fast Acting Insulin Formulations May Improve the T1D Treatment Landscape
1.5 There remains an opportunity for regenerative beta cell therapies
1.6 What do doctors think?
3 Overview of the disease
3.1 Etiology and pathophysiology
3.1.3 Biomarkers for monitoring islet autoreactivity in type 1 diabetes
4.1 Context of the disease
4.2 Risk factors and co-morbidities
4.3 Global and historical trends
4.4 Forecasting methodology
4.5 Epidemiological forecasts for T1D (2019-2029)
4.6.1 Overview of epidemiological forecasts
4.6.2 Impact of COVID-19
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease management
5.1 Diagnosis and treatment overview
5.2 Disease management in the United States
5.3 5EU disease management
5.4 Disease management in Japan
5.5 Disease management in Canada
5.6 KOL Insights on Disease Management
6 Competitive assessment
7 Assessment of unmet needs and opportunities
7.2 Disease Modifying Therapies – Beta Cell Preservation
7.3 Avoidance of hypoglycemia and management of glycemic control
7.4 Obesity, weight management and control of associated metabolic syndrome
7.5 Improving adherence and reducing the burden of insulin therapy
7.6 Care and education of patients with type 1 diabetes
8 R&D strategies
8.2 clinical trial design
9 Pipeline assessment
10 Pipeline Assessment Analysis
11 current and future players
11.2 Trading trends
11.3 Assessment of Sanofi’s portfolio, 2021
11.4 Evaluation of the Eli Lilly portfolio, 2021
11.5 Assessment of the Novo Nordisk portfolio, 2021
11.6 Johnson and Johnson Portfolio Assessment, 2021
11.7 Assessment of Lexicon Pharmaceuticals Portfolio, 2021
11.8 AstraZeneca, 2021
11.9 Mannkind Corporation, 2021
11.10 Assessment of Diasome Pharmaceuticals Portfolio, 2021
11.11 Evaluation of the Adocia portfolio, 2021
11.12 Evaluation of the Biocon portfolio, 2021
11.13 Assessment of the Diamyd medical portfolio, 2021
11.14 Zealand Pharma Portfolio Assessment, 2021
11.15 Evaluation of the vTv Therapeutics portfolio, 2021
11.16 Assessment of Provention’s biological portfolio, 2021
11.17 Evaluation of the Dompe Farmaceuti portfolio, 2021
11.18 Assessment of the PolTreg portfolio, 2021
11.19 Evaluation of the CellTrans portfolio, 2021
12 Market Outlook
12.1 Global markets
12.1.2 Drivers and Obstacles – Global Issues
12.2 United States
For more information on this report, visit https://www.researchandmarkets.com/r/u03c9